The University of Southampton
University of Southampton Institutional Repository

An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses

An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses
An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses

Broadly neutralizing antibodies (bNAbs) have demonstrated protective effects against HIV-1 in primate studies and recent human clinical trials. Elite neutralizers are potential candidates for isolation of HIV-1 bNAbs. The coexistence of bNAbs such as BG18 with neutralization-susceptible autologous viruses in an HIV-1-infected adult elite controller has been suggested to control viremia. Disease progression is faster in HIV-1-infected children than in adults. Plasma bNAbs with multiple epitope specificities are developed in HIV-1 chronically infected children with more potency and breadth than in adults. Therefore, we evaluated the specificity of plasma neutralizing antibodies of an antiretroviral-naive HIV-1 clade C chronically infected pediatric elite neutralizer, AIIMS_330. The plasma antibodies showed broad and potent HIV-1 neutralizing activity with >87% (29/33) breadth, a median inhibitory dilution (ID50) value of 1,246, and presence of N160 and N332 supersite-dependent HIV-1 bNAbs. The sorting of BG505.SOSIP.664.C2 T332N gp140 HIV-1 antigen-specific single B cells of AIIMS_330 resulted in the isolation of an HIV-1 N332 supersite-dependent bNAb, AIIMS-P01. The AIIMS-P01 neutralized 67% of HIV-1 cross-clade viruses, exhibited substantial indels despite limited somatic hypermutations, interacted with native-like HIV-1 trimer as observed in negative stain electron microscopy, and demonstrated high binding affinity. In addition, AIIMS-P01 neutralized the coexisting and evolving autologous viruses, suggesting the coexistence of vulnerable autologous viruses and HIV-1 bNAbs in the AIIMS_330 pediatric elite neutralizer. Such pediatric elite neutralizers can serve as potential candidates for isolation of novel HIV-1 pediatric bNAbs and for understanding the coevolution of virus and host immune response.IMPORTANCE More than 50% of the HIV-1 infections globally are caused by clade C viruses. To date, there is no effective vaccine to prevent HIV-1 infection. Based on the structural information of the currently available HIV-1 bNAbs, attempts are under way to design immunogens that can elicit correlates of protection upon vaccination. Here, we report the isolation and characterization of an HIV-1 N332 supersite-dependent bNAb, AIIMS-P01, from a clade C chronically infected pediatric elite neutralizer. The N332 supersite is an important epitope and is one of the current HIV-1 vaccine targets. AIIMS-P01 potently neutralized the contemporaneous and autologous evolving viruses and exhibited substantial indels despite low somatic hypermutations. Taken together with the information on infant bNAbs, further isolation and characterization of bNAbs contributing to the plasma breadth in HIV-1 chronically infected children may help provide a better understanding of their role in controlling HIV-1 infection.

Adult, Anti-Retroviral Agents, Antibodies, Monoclonal/immunology, Antibodies, Neutralizing/immunology, Biological Evolution, Child, Epitopes/immunology, Female, HIV Antibodies/immunology, HIV Infections/virology, HIV Seropositivity, HIV-1/immunology, Humans, Male, Neutralization Tests, Vaccination, Viremia, env Gene Products, Human Immunodeficiency Virus/immunology
0022-538X
Kumar, Sanjeev
72adbe62-7c8b-4430-aab6-6e54e94b2a91
Panda, Harekrushna
3927b20c-99c9-4df2-8874-db99dd961ec4
Makhdoomi, Muzamil Ashraf
19dea238-9359-4412-aae1-df8e74812525
Mishra, Nitesh
296376dd-f36f-4b32-a250-ff56067067b7
Safdari, Haaris Ahsan
392ef630-353d-48e4-b537-4d76ffe0e08e
Chawla, Himanshi
07b9e983-4c35-4314-999d-fe3222a6c03b
Aggarwal, Heena
675f9bb1-a923-4b04-a98c-8734ac05e85c
Reddy, Elluri Seetharami
2d2e4bbf-af76-409d-b828-6501d619b377
Lodha, Rakesh
cdfb40fa-c83b-4ec0-bfe2-33a589209a62
Kumar Kabra, Sushil
750c3597-145e-43f2-82d4-98e8d5826894
Chandele, Anmol
2fcbb8bf-0c7a-4f2a-b67e-b9464f46507d
Dutta, Somnath
ba48fb38-ef6a-4dc1-ae11-e2b91c00c2ea
Luthra, Kalpana
40fc2436-ee10-4d8b-a414-70e7214a2bf2
Kumar, Sanjeev
72adbe62-7c8b-4430-aab6-6e54e94b2a91
Panda, Harekrushna
3927b20c-99c9-4df2-8874-db99dd961ec4
Makhdoomi, Muzamil Ashraf
19dea238-9359-4412-aae1-df8e74812525
Mishra, Nitesh
296376dd-f36f-4b32-a250-ff56067067b7
Safdari, Haaris Ahsan
392ef630-353d-48e4-b537-4d76ffe0e08e
Chawla, Himanshi
07b9e983-4c35-4314-999d-fe3222a6c03b
Aggarwal, Heena
675f9bb1-a923-4b04-a98c-8734ac05e85c
Reddy, Elluri Seetharami
2d2e4bbf-af76-409d-b828-6501d619b377
Lodha, Rakesh
cdfb40fa-c83b-4ec0-bfe2-33a589209a62
Kumar Kabra, Sushil
750c3597-145e-43f2-82d4-98e8d5826894
Chandele, Anmol
2fcbb8bf-0c7a-4f2a-b67e-b9464f46507d
Dutta, Somnath
ba48fb38-ef6a-4dc1-ae11-e2b91c00c2ea
Luthra, Kalpana
40fc2436-ee10-4d8b-a414-70e7214a2bf2

Kumar, Sanjeev, Panda, Harekrushna, Makhdoomi, Muzamil Ashraf, Mishra, Nitesh, Safdari, Haaris Ahsan, Chawla, Himanshi, Aggarwal, Heena, Reddy, Elluri Seetharami, Lodha, Rakesh, Kumar Kabra, Sushil, Chandele, Anmol, Dutta, Somnath and Luthra, Kalpana (2019) An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses. Journal of Virology, 93 (4). (doi:10.1128/JVI.01495-18).

Record type: Article

Abstract

Broadly neutralizing antibodies (bNAbs) have demonstrated protective effects against HIV-1 in primate studies and recent human clinical trials. Elite neutralizers are potential candidates for isolation of HIV-1 bNAbs. The coexistence of bNAbs such as BG18 with neutralization-susceptible autologous viruses in an HIV-1-infected adult elite controller has been suggested to control viremia. Disease progression is faster in HIV-1-infected children than in adults. Plasma bNAbs with multiple epitope specificities are developed in HIV-1 chronically infected children with more potency and breadth than in adults. Therefore, we evaluated the specificity of plasma neutralizing antibodies of an antiretroviral-naive HIV-1 clade C chronically infected pediatric elite neutralizer, AIIMS_330. The plasma antibodies showed broad and potent HIV-1 neutralizing activity with >87% (29/33) breadth, a median inhibitory dilution (ID50) value of 1,246, and presence of N160 and N332 supersite-dependent HIV-1 bNAbs. The sorting of BG505.SOSIP.664.C2 T332N gp140 HIV-1 antigen-specific single B cells of AIIMS_330 resulted in the isolation of an HIV-1 N332 supersite-dependent bNAb, AIIMS-P01. The AIIMS-P01 neutralized 67% of HIV-1 cross-clade viruses, exhibited substantial indels despite limited somatic hypermutations, interacted with native-like HIV-1 trimer as observed in negative stain electron microscopy, and demonstrated high binding affinity. In addition, AIIMS-P01 neutralized the coexisting and evolving autologous viruses, suggesting the coexistence of vulnerable autologous viruses and HIV-1 bNAbs in the AIIMS_330 pediatric elite neutralizer. Such pediatric elite neutralizers can serve as potential candidates for isolation of novel HIV-1 pediatric bNAbs and for understanding the coevolution of virus and host immune response.IMPORTANCE More than 50% of the HIV-1 infections globally are caused by clade C viruses. To date, there is no effective vaccine to prevent HIV-1 infection. Based on the structural information of the currently available HIV-1 bNAbs, attempts are under way to design immunogens that can elicit correlates of protection upon vaccination. Here, we report the isolation and characterization of an HIV-1 N332 supersite-dependent bNAb, AIIMS-P01, from a clade C chronically infected pediatric elite neutralizer. The N332 supersite is an important epitope and is one of the current HIV-1 vaccine targets. AIIMS-P01 potently neutralized the contemporaneous and autologous evolving viruses and exhibited substantial indels despite low somatic hypermutations. Taken together with the information on infant bNAbs, further isolation and characterization of bNAbs contributing to the plasma breadth in HIV-1 chronically infected children may help provide a better understanding of their role in controlling HIV-1 infection.

This record has no associated files available for download.

More information

Published date: 15 February 2019
Keywords: Adult, Anti-Retroviral Agents, Antibodies, Monoclonal/immunology, Antibodies, Neutralizing/immunology, Biological Evolution, Child, Epitopes/immunology, Female, HIV Antibodies/immunology, HIV Infections/virology, HIV Seropositivity, HIV-1/immunology, Humans, Male, Neutralization Tests, Vaccination, Viremia, env Gene Products, Human Immunodeficiency Virus/immunology

Identifiers

Local EPrints ID: 455473
URI: http://eprints.soton.ac.uk/id/eprint/455473
ISSN: 0022-538X
PURE UUID: c69305a9-2c59-489f-80bc-0f192a9ca11f
ORCID for Himanshi Chawla: ORCID iD orcid.org/0000-0001-9828-6593

Catalogue record

Date deposited: 22 Mar 2022 17:43
Last modified: 17 Mar 2024 03:57

Export record

Altmetrics

Contributors

Author: Sanjeev Kumar
Author: Harekrushna Panda
Author: Muzamil Ashraf Makhdoomi
Author: Nitesh Mishra
Author: Haaris Ahsan Safdari
Author: Himanshi Chawla ORCID iD
Author: Heena Aggarwal
Author: Elluri Seetharami Reddy
Author: Rakesh Lodha
Author: Sushil Kumar Kabra
Author: Anmol Chandele
Author: Somnath Dutta
Author: Kalpana Luthra

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×